Simulations Plus Receives Grant for Drug Formulation Innovation
Simulations Plus, Inc. (Nasdaq: SLP), a recognized leader in biosimulation solutions, has exciting news! The company has been awarded a new grant from the U.S. Food and Drug Administration (FDA). This funding came through a partnership with the University of Strathclyde and InnoGI Technologies. The aim of this initiative is to validate and enhance methods for predicting the behavior of complex drug formulations, specifically focusing on amorphous solid dispersions (ASD).
Understanding Amorphous Solid Dispersions
ASDs are crucial in the drug development process as they help in improving solubility and enhancing the bioavailability of drugs. The newly funded project seeks to explore these formulations under varying conditions such as differing pH levels and food interactions. By employing a mix of innovative in vitro testing along with mechanistic modeling and simulation techniques, Simulations Plus aims to forge ahead in understanding how these drugs perform in real-world situations.
Collaboration with Institutions
Professor Hannah Batchelor at the University of Strathclyde will steer the analysis of the various ASD formulations. InnoGI Technologies will contribute by leveraging their advanced testing technologies under diverse gastric conditions using their SurroGUT™ platform. This collaborative approach ensures a comprehensive understanding of how formulation variables can impact drug performance.
Advancements in Modeling and Simulation
To connect the outcomes from these experiments, physiologically based pharmacokinetic (PBPK) models will be developed using the renowned GastroPlus® software. This vital step will integrate in vitro dissolution data with in vivo pharmacokinetic data, ultimately leading to the development of in vitro-in vivo extrapolation (IVIVE) methods. By simulating virtual bioequivalence trials, the project will facilitate rapid assessment of ASD formulation efficiency, subsequently expediting the adjustment processes for both innovator and generic products.
Key Insights from Experts
Dr. Maxime Le Merdy, the Director of PBPK Collaborations at Simulations Plus and the lead investigator of this grant, expressed enthusiasm regarding the research. "This is a significant step towards refining our drug development strategies. By innovating a new IVIVE methodology specifically for ASD products, we can optimize our approach to formulation development and enhance our understanding of factors affecting in vivo performance," he noted.
Strengthening Industry Relationships
This research project will not only rely on the collaboration of Simulations Plus but will also benefit from direct involvement with FDA scientific staff. This partnership illustrates a true industry-academia-regulatory triangle, driving innovation towards safer and more efficient drug therapies.
Prof. Batchelor emphasized, "This collaboration will significantly push the boundaries of our research and help us innovate drug development. Combining InnoGI’s in vitro technologies with our modeling capabilities and clinical insights will lead to faster and more effective health solutions."
The Role of Technology in Drug Development
As the complexities of oral formulation development continue to increase, it becomes essential to adopt advanced technologies. This initiative reflects a commitment to bridging gaps between in vitro testing and in vivo performance, showcasing the industry's dedication to impactful drug development.
Company Backgrounds
Simulations Plus has been in operation for over 25 years, offering its expertise in biosimulation to clients around the world. This includes not just drug discovery and development but also support for regulatory processes. The focus on machine learning and pharmacokinetics makes their approach beneficial for multiple stakeholders in the biopharma landscape.
The University of Strathclyde contributes to this field with research directing efforts towards child-appropriate medications, maximizing therapeutic benefits while minimizing risks.
InnoGI Technologies stands out in the GI testing arena, having developed unique models that simulate the human gastrointestinal processes, enhancing the efficacy of drug testing.
Frequently Asked Questions
What is the purpose of the FDA grant awarded to Simulations Plus?
The FDA grant aims to enhance methods for predicting the behavior of complex drug formulations through innovative research on amorphous solid dispersions.
What are amorphous solid dispersions (ASDs)?
ASDs are formulations designed to improve solubility and bioavailability for drugs, which are essential for effective medication delivery.
Which institutions are collaborating on this project?
The project is a collaboration between Simulations Plus, the University of Strathclyde, and InnoGI Technologies.
How does the GastroPlus® software contribute to the research?
GastroPlus® helps in developing physiologically based pharmacokinetic models to link in vitro results with in vivo pharmacokinetics, facilitating the prediction of drug performance.
How will this research impact drug development in the future?
This research is expected to enhance drug formulation processes, reduce costs, and accelerate time-to-market for both innovator and generic drug products.
